// App-Quantinova.ai

AB0293 (2021) : IDENTIFYING PREDICTORS OF SHORT-TERM RESPONSE TO RITUXIMAB IN PRIMARY SJOGREN’S SYNDROME

Researchers

Presenter

  • S. Pepple

Principal Investigators

  • J. Arnold

  • E. Vital

  • A. Rawstron

  • C. Pease

  • S. Dass

  • P. Emery

  • M. Y. MD Yusof

Medical Centers

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • Leeds Teaching Hospitals NHS Trust and NIHR Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom

  • Leeds Teaching Hospitals NHS Trust, Haematological Malignancy Diagnostic Service, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Sjogren's syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • Observational

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Roche

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved